PODD Insulet Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: PODD

Price (delayed)

$162.06

Market cap

$11.23B

P/E Ratio

37.69

Dividend/share

N/A

EPS

$4.3

Enterprise value

$11.69B

?
Relative Growth: Rel. Growth: 98
Relative Strength: Rel. Strength: 9
Relative Valuation: Rel. Valuation: 32
Relative Profitability: Rel. Profitability: 78

Insulet Corporation , headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod ...

Highlights
PODD's price to earnings (P/E) is 98% lower than its 5-year quarterly average of 2218.9 and 52% lower than its last 4 quarters average of 77.8
The company's debt fell by 44% YoY
PODD's net income is down by 25% year-on-year but it is up by 23% since the previous quarter
The EPS has contracted by 25% YoY but it has grown by 23% from the previous quarter
Insulet's quick ratio has plunged by 54% YoY and by 18% from the previous quarter
The equity is down by 14% QoQ and by 2.1% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.myomnipod.com
Peers: ICUI DCTH TNDM DXCM

Key stats

What are the main financial stats of PODD

PODD stock price

How has the Insulet stock price performed over time
Intraday
0.48%
1 week
1.43%
1 month
8.26%
1 year
-43.99%
YTD
-42.98%
QTD
6.44%

Financial performance

How have Insulet's revenue and profit performed over time
Revenue
$2.9B
Gross profit
$2.06B
Operating income
$507.2M
Net income
$302.8M
Gross margin
71%
Net margin
10.4%
Insulet's operating income has increased by 49% YoY and by 7% QoQ
The company's net margin fell by 43% YoY but it rose by 14% QoQ
PODD's gross profit is up by 33% YoY and by 6% from the previous quarter
PODD's revenue is up by 32% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does PODD's price correlate with its fundamentals

Growth

What is Insulet's growth rate over time

Valuation

What is Insulet stock price valuation
PODD P/E details
P/E
37.69
P/B
8.76
P/S
3.91
EV/EBIT
24.93
EV/EBITDA
20.73
EV/Sales
4.03
PODD's price to earnings (P/E) is 98% lower than its 5-year quarterly average of 2218.9 and 52% lower than its last 4 quarters average of 77.8
The EPS has contracted by 25% YoY but it has grown by 23% from the previous quarter
PODD's price to book (P/B) is 65% less than its 5-year quarterly average of 25.1 and 37% less than its last 4 quarters average of 13.8
The equity is down by 14% QoQ and by 2.1% YoY
PODD's price to sales (P/S) is 64% lower than its 5-year quarterly average of 11.0 and 49% lower than its last 4 quarters average of 7.6
PODD's revenue is up by 32% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is Insulet business performance
Insulet's return on invested capital has surged by 61% YoY and by 25% QoQ
PODD's ROE is down by 38% YoY but it is up by 23% QoQ
The return on assets has increased by 28% since the previous quarter but it has declined by 26% year-on-year
The ROS has grown by 10% from the previous quarter and by 7% YoY

Dividends

What is PODD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PODD.

Financial health

How did Insulet financials performed over time
The total assets is 77% higher than the total liabilities
Insulet's quick ratio has plunged by 54% YoY and by 18% from the previous quarter
The current ratio has decreased by 44% YoY and by 11% from the previous quarter
The company's debt is 27% lower than its equity
The company's debt fell by 44% YoY
The debt to equity has decreased by 43% YoY but it has increased by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.